HSP90 inhibition in the mouse spinal cord enhances opioid signaling by suppressing an AMPK-mediated negative feedback

Katherin A Gabriel1, John M Streicher1,2

  • 1Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ, USA.

Science Signaling
|April 11, 2023
PubMed

Insights

Inhibiting HSP90 enhances opioid pain relief by disrupting an AMPK-mediated feedback loop in spinal cord CGRP neurons. This strategy overcomes opioid tolerance and improves pain management.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Molecular Biology

Background:

  • Chronic opioid use leads to tolerance, limiting pain management efficacy.
  • HSP90 inhibition previously enhanced opioid analgesia via ERK activation.
  • The precise molecular mechanism remained unclear.

Purpose of the Study:

  • To elucidate the mechanism by which HSP90 inhibition enhances opioid efficacy.
  • To investigate the role of AMPK in opioid-induced tolerance and HSP90 inhibition effects.

Main Methods:

  • Used intrathecal administration of HSP90 inhibitor (17-AAG) and morphine in mice.
  • Assessed AMPK subunit abundance and phosphorylation in spinal cord tissue.
  • Utilized AMPK activators and inhibitors to modulate pathway activity.
  • Performed genetic knockdown of AMPK in CGRP-positive neurons.

Main Results:

  • HSP90 inhibition reduced spinal cord AMPK β1 subunit abundance.
  • AMPK activation suppressed 17-AAG's antinociceptive effects, while inhibition enhanced them.
  • Opioid treatment increased phosphorylated AMPK in CGRP neurons.
  • AMPK knockdown in CGRP neurons potentiated morphine's antinociceptive effects.

Conclusions:

  • AMP-activated protein kinase (AMPK) mediates an opioid-induced negative feedback loop in spinal cord CGRP neurons.
  • HSP90 inhibition disrupts this AMPK-mediated feedback loop, enhancing opioid efficacy.
  • Targeting the HSP90-AMPK-ERK pathway offers a strategy to overcome opioid tolerance.

Related Concept Videos

Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
691
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
1.2K
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
360
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.1K